Results 301 to 310 of about 58,087 (312)
Some of the next articles are maybe not open access.
Peptides for Radionuclide Therapy
2008Somatostatin receptor-targeting peptides are widely being used for imaging and therapy of neuroendocrine tumors. Peptide receptor radionuclide therapy (PRRT) with e.g. 177Lu labeled somatostatin analogues in neuroendocrine tumor patients has resulted in symptomatic improvement, prolonged survival and enhanced quality of life.
Roelf Valkema +5 more
openaire +2 more sources
Bone-Seeking Radionuclide for Therapy
2016Ionising radiation is utilised in a variety of situations in the management of prostate cancer. Beyond the scope of this book is the use of brachytherapy and external beam radiotherapy (EBRT) as efficacious, radical treatment modalities in the management of localised prostate cancer. Earlier chapters have covered the use of EBRT as a therapeutic option
O’Sullivan, Joe, Turner, Phil
openaire +3 more sources
Targeted Radionuclide Therapy in Glioblastoma
ACS Applied Materials & InterfacesDespite the development of various novel therapies, glioblastoma (GBM) remains a devastating disease, with a median survival of less than 15 months. Recently, targeted radionuclide therapy has shown significant progress in treating solid tumors, with the approval of Lutathera for neuroendocrine tumors and Pluvicto for prostate cancer by the US Food and
Xiaobin Zhao +7 more
openaire +2 more sources
Bystander Effects and Radionuclide Therapy
2008The standard paradigm for radiation effects in biological systems is that direct DNA damage within the nucleus of a cell is required to trigger the down-stream biological consequences. However, significant evidence has been obtained for the presence of bystander effects where cells respond to the fact that their neighbours have been irradiated. As well
openaire +2 more sources
Future of radionuclide therapy
International Congress Series, 2002M Fischer, W Becker
openaire +2 more sources